- Home
- LSF vs SNTI Comparison
LSF vs SNTI Comparison
Compare LSF & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | SNTI |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 24.5M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LSF | SNTI |
|---|---|---|
| Price | $2.48 | $0.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $9.00 |
| AVG Volume (30 Days) | 33.8K | ★ 101.8K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,295,137.00 | N/A |
| Revenue This Year | $15.87 | N/A |
| Revenue Next Year | $14.98 | $150.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.50 | N/A |
| 52 Week Low | $1.98 | $0.80 |
| 52 Week High | $7.94 | $5.10 |
Technical Indicators
Market Signals| Indicator | LSF | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 42.32 | 42.51 |
| Support Level | $2.41 | $0.80 |
| Resistance Level | $2.76 | $1.02 |
| Average True Range (ATR) | 0.20 | 0.05 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 25.00 | 28.72 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.